NESS ZIONA, Israel, April 18, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies Ltd. (NASDAQ: SLGL) ("Sol–Gel" or the "Company"), a clinical–stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that management will participate in the BMO–sponsored Class of 2018 Biotech IPOs Investor Day taking place in New York, NY.
Dr. Alon Seri–Levy, Chief Executive Officer, will provide a business overview and update on the Company's pipeline programs on Friday, April 26th at 10:30 a.m. ET.
A live audio webcast of the presentation will be available in the Investors/Events & Presentations section of the Sol–Gel Technologies website at http://www.sol–gel.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Sol–Gel Technologies
Sol–Gel is a clinical–stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol–Gel's current product candidate pipeline consists of late–stage branded product candidates that leverage our proprietary, silica–based microencapsulation technology platform, and several generic product candidates across multiple indications. For additional information, please visit www.sol–gel.com.
For further information, please contact:
Chief Financial Officer
Patricia L. Bank
Westwicke, an ICR Company